Van Kerrebroeck PEV - Search Results

1

New Technologies and Applications in Sacral Neuromodulation: An Update.

De Wachter S, Knowles CH, Elterman DS, Kennelly MJ, Lehur PA, Matzel KE, Engelberg S, Van Kerrebroeck PEV. De Wachter S, et al. Among authors: van kerrebroeck pev. Adv Ther. 2020 Feb;37(2):637-643. doi: 10.1007/s12325-019-01205-z. Epub 2019 Dec 24. Adv Ther. 2020. PMID: 31875299 Free PMC article. Review.

2

Buttock placement of the implantable pulse generator: a new implantation technique for sacral neuromodulation--a multicenter study.

Scheepens WA, Weil EH, van Koeveringe GA, Rohrmann D, Hedlund HE, Schurch B, Ostardo E, Pastorello M, Ratto C, Nordling J, van Kerrebroeck PE. Scheepens WA, et al. Eur Urol. 2001 Oct;40(4):434-8. doi: 10.1159/000049812. Eur Urol. 2001. PMID: 11713399 Clinical Trial.

3

Predictive factors for sacral neuromodulation in chronic lower urinary tract dysfunction.

Scheepens WA, Jongen MM, Nieman FH, de Bie RA, Weil EH, van Kerrebroeck PE. Scheepens WA, et al. Urology. 2002 Oct;60(4):598-602. doi: 10.1016/s0090-4295(02)01841-1. Urology. 2002. PMID: 12385915

4

Sacral nerve stimulation for neuromodulation of the lower urinary tract.

Oerlemans DJ, van Kerrebroeck PE. Oerlemans DJ, et al. Neurourol Urodyn. 2008;27(1):28-33. doi: 10.1002/nau.20459. Neurourol Urodyn. 2008. PMID: 17563110 Review.

5

Changes in bladder innervation in a mouse model of Alzheimer's disease.

Biallosterski BT, de Wachter SG, van Koeveringe GA, van Kerrebroeck PE, de Vente J, Mulder MT, Gillespie JI. Biallosterski BT, et al. J Chem Neuroanat. 2010 May;39(3):204-10. doi: 10.1016/j.jchemneu.2009.12.001. Epub 2009 Dec 16. J Chem Neuroanat. 2010. PMID: 20025962

6

Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.

Leong RK, De Wachter SG, van Kerrebroeck PE. Leong RK, et al. Urol Int. 2010;84(3):245-53. doi: 10.1159/000288223. Epub 2010 Apr 13. Urol Int. 2010. PMID: 20389150 Free article. Review.

7

Long-term results of sacral neuromodulation with the tined lead procedure.

Marcelissen TA, Leong RK, de Bie RA, van Kerrebroeck PE, de Wachter SG. Marcelissen TA, et al. J Urol. 2010 Nov;184(5):1997-2000. doi: 10.1016/j.juro.2010.06.142. Epub 2010 Sep 18. J Urol. 2010. PMID: 20850820

8

The relationship between prostaglandin E receptor 1 and cyclooxygenase I expression in guinea pig bladder interstitial cells: proposition of a signal propagation system.

Rahnama'i MS, de Wachter SG, van Koeveringe GA, van Kerrebroeck PE, de Vente J, Gillespie JI. Rahnama'i MS, et al. J Urol. 2011 Jan;185(1):315-22. doi: 10.1016/j.juro.2010.09.005. J Urol. 2011. PMID: 21075388

9

Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.

Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Leong RK, et al. BJU Int. 2011 Aug;108(4):558-64. doi: 10.1111/j.1464-410X.2010.09905.x. Epub 2010 Dec 16. BJU Int. 2011. PMID: 21166750

10

Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey.

Leong RK, Marcelissen TA, Nieman FH, De Bie RA, Van Kerrebroeck PE, De Wachter SG. Leong RK, et al. J Urol. 2011 Feb;185(2):588-92. doi: 10.1016/j.juro.2010.09.090. Epub 2010 Dec 18. J Urol. 2011. PMID: 21168881

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

133 results

Search Page

Filters